In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) ...

The therapy for early-stage choroidal melanomas preserved vision in 90% of patients with no serious treatment-related adverse effects.

Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line treatment for early-stage choroidal melanoma: Boston Saturday, September 14, 2024, ...

Eye pain occurred in 9% of patients and was mild (Grade 1). Importantly, no treatment-related posterior inflammation events (no vitritis, choroiditis, retinitis, retinal pigment epithelium changes, or ...